Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data

Aims : Immunohistochemistry is frequently employed to aid the distinction between mesothelioma and pulmonary adenocarcinoma metastatic to the pleura, but there is uncertainty as to which antibodies are most useful. We analysed published data in order to establish sensitivity and specificity of antibodies used to distinguish between these tumours with a view to defining the most appropriate immunohistochemical panel to use when faced with this diagnostic problem.

[1]  G. Pinkus,et al.  The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma , 2002, Cancer.

[2]  M. Wick Immunophenotyping of malignant mesothelioma. , 1997, The American journal of surgical pathology.

[3]  P. Fetsch,et al.  Hyaluronate binding probe and CD44 in the differential diagnosis of malignant effusions: Disappointing results in cytology material , 1998, Diagnostic cytopathology.

[4]  C. Comin,et al.  Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. , 2001, Human pathology.

[5]  A. Vortmeyer,et al.  Immunocytochemical differential diagnosis of diffuse malignant pleural mesotheliomas--a clinicomorphological study of 158 cases. , 1991, Anticancer research.

[6]  F. Hirsch,et al.  Are pathologists biased by clinical information?: A blinded cross-over study of the histopathological diagnosis of mesothelial tumours versus pulmonary adenocarcinoma. , 1994, Lung cancer.

[7]  Hector Battifora,et al.  Tumors of the serosal membranes , 1995 .

[8]  N. Ordóñez Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[9]  S. Mills,et al.  Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases. , 1990, Human pathology.

[10]  R. Attanoos,et al.  Primary sarcomas of the lung: a clinicopathological and immunohistochemical study of 14 cases , 1996, Histopathology.

[11]  J. Churg,et al.  Histochemistry in the diagnosis of malignant mesothelioma. , 1973, Annals of clinical and laboratory science.

[12]  J. Said,et al.  Keratin in human lung tumors. Patterns of localization of different-molecular-weight keratin proteins. , 1983, The American journal of pathology.

[13]  Leers,et al.  E‐cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma , 1998, Histopathology.

[14]  W. Kwee,et al.  Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis , 2004, Virchows Archiv A.

[15]  H. Loosli,et al.  Immunohistological study of malignant diffuse mesotheliomas of the pleura , 1984, Histopathology.

[16]  M. Kaneko,et al.  Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. , 1989, The American journal of pathology.

[17]  A. Hjerpe,et al.  An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. , 2000, American journal of clinical pathology.

[18]  I. Downie,et al.  Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. , 2001, American journal of clinical pathology.

[19]  J. Oates,et al.  Anti‐cytokeratin 5/6: a positive marker for epithelioid mesothelioma , 1997, Histopathology.

[20]  L. Weiss,et al.  Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. , 1992, Human pathology.

[21]  G. Sterrett,et al.  Detection of Tissue Cea‐Like Substance as an Aid in the Differential Diagnosis of Malignant Mesothelioma , 1982, Pathology.

[22]  C. Otis,et al.  Immunohistochemical Evaluation of Pleural Mesothelioma and Pulmonary Adenocarcinoma: A Bi-institutional Study of 47 Cases , 1987, The American journal of surgical pathology.

[23]  S. Sahn Malignancy metastatic to the pleura. , 1998, Clinics in chest medicine.

[24]  H. Battifora,et al.  Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach , 1985, Cancer.

[25]  P. Cagle,et al.  p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. , 1994, Human pathology.

[26]  R. Attanoos,et al.  CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma , 1997, Histopathology.

[27]  J. Bellocq,et al.  [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects]. , 1990, Annales de pathologie.

[28]  N. Ordóñez The Immunohistochemical Diagnosis of Mesothelioma: Differentiation of Mesothelioma and Lung Adenocarcinoma , 1989, The American journal of surgical pathology.

[29]  P. Betta,et al.  Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies. , 1997, Human pathology.

[30]  P. Betta,et al.  New marker for mesothelioma: an immunoperoxidase study. , 1986, Journal of clinical pathology.

[31]  M. Pfaltz,et al.  Immunohistochemistry in the diagnosis of malignant mesothelioma , 2004, Virchows Archiv A.

[32]  W. Grigioni,et al.  Immunohistochemical Panels For Differentiating Epithelial Malignant Mesothelioma From Lung Adenocarcinoma: A Study With Logistic Regression Analysis , 2001, The American journal of surgical pathology.

[33]  M. Miettinen,et al.  Expression of Calretinin, Thrombomodulin, Keratin 5, and Mesothelin in Lung Carcinomas of Different Types: An Immunohistochemical Analysis of 596 Tumors in Comparison With Epithelioid Mesotheliomas of the Pleura , 2003, The American journal of surgical pathology.

[34]  B Terracini,et al.  Malignant mesothelioma of the pleura: interobserver variability. , 1995, Journal of clinical pathology.

[35]  N. Ordóñez,et al.  Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. , 2000, The American journal of surgical pathology.

[36]  Klaus Kayser,et al.  Glyco‐ and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients , 2001, The Journal of pathology.

[37]  V. Roggli,et al.  Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian Mesothelioma Panel. , 1991, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[38]  Y. Shimosato,et al.  Histological Typing of Lung and Pleural Tumours , 1999, World Health Organization.

[39]  P. Hasleton,et al.  Immunohistochemistry and the diagnosis of malignant mesothelioma , 2001, Histopathology.

[40]  S. Hirohashi,et al.  Expression of Vimentin in Surgically Resected Adenocarcinomas and Large Cell Carcinomas of Lung , 1986, The American journal of surgical pathology.

[41]  N. Ordóñez,et al.  Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. , 1998, The American journal of surgical pathology.

[42]  A. Hjerpe,et al.  Immunohistochemical reactivity in mesothelioma and adenocarcinoma: A stepwise logistic regression analysis , 1994, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[43]  Phil Gold,et al.  SPECIFIC CARCINOEMBRYONIC ANTIGENS OF THE HUMAN DIGESTIVE SYSTEM , 1965, The Journal of experimental medicine.

[44]  N. Ordóñez,et al.  Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. , 1992, The American journal of pathology.

[45]  J. Peto,et al.  Continuing increase in mesothelioma mortality in Britain , 1995, The Lancet.

[46]  K. Gatter,et al.  Immunohistological staining of reactive mesothelium, mesothelioma, and lung carcinoma with a panel of monoclonal antibodies. , 1987, Journal of clinical pathology.

[47]  P. Majerus,et al.  Thrombomodulin as a marker for vascular tumors. Comparative study with factor VIII and Ulex europaeus I lectin. , 1987, American journal of clinical pathology.

[48]  Rogers Spencer's pathology of the lung , 1999, Histopathology.

[49]  F. Puglisi,et al.  TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. , 1998, Cancer letters.

[50]  M. Jaurand,et al.  The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. , 1995, Human pathology.

[51]  L. Happerfield,et al.  The differential diagnosis of epithelial‐type mesothelioma from adenocarcinoma and reactive mesothelial proliferation , 1991, The Journal of pathology.

[52]  K. Kerr,et al.  HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura. , 1997, Journal of clinical pathology.

[53]  A. Churg Immunohistochemical staining for vimentin and keratin in malignant mesothelioma , 1985, The American journal of surgical pathology.

[54]  K. Johnson,et al.  Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues. , 1997, Human pathology.

[55]  D. Allred,et al.  Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. , 2009, Archives of pathology & laboratory medicine.

[56]  J. Whitsett,et al.  Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. , 1999, Human pathology.

[57]  N. Ordóñez The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma , 2003, The American journal of surgical pathology.

[58]  S. Hirohashi,et al.  Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies. , 1989, Human pathology.

[59]  G. Viale,et al.  Calretinin: a novel immunocytochemical marker for mesothelioma. , 1996, The American journal of surgical pathology.

[60]  George L. Wright,et al.  Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma , 1991, Cancer.

[61]  A. Niezabitowski,et al.  Calretinin and Other Mesothelioma Markers in Synovial Sarcoma: Analysis of Antigenic Similarities and Differences With Malignant Mesothelioma , 2001, The American journal of surgical pathology.

[62]  H. Moch,et al.  Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: immunohistochemical findings , 2005, Virchows Archiv A.

[63]  Edwards,et al.  HBME‐1, MOC‐31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma , 2000, Histopathology.

[64]  K. Müller,et al.  [Immunohistochemical studies for the differential diagnosis of primary and secondary pleural tumors]. , 1986, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[65]  V. Roggli,et al.  The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). , 1986, The American journal of pathology.

[66]  J. Schlom,et al.  Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: An immunohistochemical approach using a panel of monoclonal antibodies , 1990, Journal of surgical oncology.

[67]  J. Dahlstrom,et al.  DISTINCTIVE MICROVILLOUS BRUSH BORDER STAINING WITH HBME‐1 DISTINGUISHES PLEURAL MESOTHELIOMAS FROM PULMONARY ADENOCARCINOMAS , 2001, Pathology.

[68]  P. Lee,et al.  Interpretation and Uses of Medical Statistics. , 1969 .

[69]  T. H. van der Kwast,et al.  Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma , 1991, The Journal of pathology.

[70]  P. Hasleton,et al.  Immunoreactivity for cadherins, HGF/SF, met, and erbB‐2 in pleural malignant mesotheliomas , 2000, Histopathology.

[71]  A. Churg,et al.  Carcinoembryonic antigen and milk-fat globule protein staining of malignant mesothelioma and adenocarcinoma of the lung. , 1987, Archives of pathology & laboratory medicine.

[72]  P. Hasleton,et al.  Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions. , 1990, The European respiratory journal.

[73]  C. Kortsik,et al.  Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3—A new tumor marker , 2008, Lung.

[74]  J. Riera,et al.  The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. , 1997, The American journal of surgical pathology.

[75]  B. Corrin,et al.  Pleural mesothelioma of epithelial type and pulmonary adenocarcinoma: An ultrastructural and cytochemical comparison , 1987, The Journal of pathology.

[76]  G. Pinkus,et al.  Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. , 1982, The American journal of pathology.

[77]  N. Ordóñez The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. , 1997, The American journal of surgical pathology.

[78]  Z. Zakov,et al.  Interpretation and Uses of Medical Statistics by Geoffrey J. Bourke, Leslie E. Daly, and James McGilvray , 1987 .

[79]  P. Vogt,et al.  The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. , 1996, Pathology, research and practice.

[80]  H. Battifora,et al.  Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen. , 1986, The American journal of pathology.

[81]  H. Stein,et al.  Ber-EP 4 : new monoclonal antibody which distinguishes epithelia from mesothelia , 2022 .

[82]  R. Stahel,et al.  Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma , 1988, International journal of cancer.

[83]  P. Chu,et al.  Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases , 2002, Modern Pathology.

[84]  B. Jasani,et al.  Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma. , 1985, Thorax.

[85]  Mayordomo,et al.  A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours , 1998, Histopathology.

[86]  C. Meijer,et al.  Simultaneous immunoenzyme staining of vimentin and cytokeratins with monoclonal antibodies as an aid in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma , 1986, Virchows Archiv. B, Cell pathology including molecular pathology.

[87]  M. Jaurand,et al.  The Mesothelial Cell and Mesothelioma , 1994 .

[88]  T. Kawai,et al.  Lectin histochemistry of normal lung and pulmonary adenocarcinoma. , 1988, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[89]  J. Morris,et al.  Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. , 1995, The American journal of pathology.

[90]  J. Legier,et al.  Immunohistochemical diagnosis of mesothelioma , 1994 .

[91]  A. Nicholson,et al.  Value of the Mesothelium-Associated Antibodies Thrombomodulin, Cytokeratin 5/6, Calretinin, and CD44H in Distinguishing Epithelioid Pleural Mesothelioma from Adenocarcinoma Metastatic to the Pleura , 2000, Modern Pathology.

[92]  S. Paulsen,et al.  The value of immunohistochemistry of pleural biopsy specimens in the differential diagnosis between malignant mesothelioma and metastatic carcinoma. , 1994, Pathology, research and practice.

[93]  R. Attanoos,et al.  Mesothelioma‐binding antibodies: thrombomodulin, OV 632 and HBME‐1 and their use in the diagnosis of malignant mesothelioma , 1996, Histopathology.

[94]  H. Hoogsteden,et al.  The influence of the diagnostic technique on the histopathological diagnosis in malignant mesothelioma , 1991, Virchows Archiv A.

[95]  D. Allred,et al.  Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. , 1993, Human pathology.

[96]  M. Gaffey,et al.  Immunoreactivity for BER‐EP4 in Adenocarcinomas, Adenomatoid Tumors, and Malignant Mesotheliomas , 1992, The American journal of surgical pathology.

[97]  L. Weiss,et al.  Ber‐EP4 Antibody as a Discriminant in the Differential Diagnosis of Malignant Mesothelioma Versus Adenocarcinoma , 1991, The American journal of surgical pathology.

[98]  A. Thor,et al.  Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1. , 1988, The American journal of pathology.

[99]  A. Hjerpe,et al.  Carcinoembryonic antigen-like reactivity in malignant mesothelioma. A comparison between different commercially available antibodies. , 1994, Cancer.

[100]  J. Bellocq,et al.  [Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies]. , 1998, Annales de pathologie.

[101]  E. van Marck,et al.  WT1 MUTATION IN MALIGNANT MESOTHELIOMA AND WT1 IMMUNOREACTIVITY IN RELATION TO p53 AND GROWTH FACTOR RECEPTOR EXPRESSION, CELL‐TYPE TRANSITION, AND PROGNOSIS , 1997, The Journal of pathology.

[102]  P. Gold,et al.  Absence of carcinoembryonic antigen‐like material in mesothelioma An immunohistochemical differentiation from other lung cancers , 1979, Cancer.

[103]  B. D. De Young,et al.  Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[104]  D. Henderson,et al.  Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. , 1998, American journal of clinical pathology.

[105]  G. Chejfec,et al.  Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12. , 1986, The American journal of pathology.

[106]  C. Esmon,et al.  Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. , 1982, The Journal of biological chemistry.

[107]  B. Jasani,et al.  The use of vimentin antibodies in the diagnosis of malignant mesothelioma , 2004, Virchows Archiv A.

[108]  B. Addis,et al.  Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies , 2002, Journal of clinical pathology.

[109]  H. Battifora,et al.  Leu-Ml Antigen in Human Neoplasms: An Immunohistologic Study of 400 Cases , 1986, The American journal of surgical pathology.

[110]  N. Ordóñez,et al.  Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. , 1998, Human pathology.

[111]  S. Tuttle,et al.  Diagnostic histochemical and immunohistochemical studies in malignant mesothelioma , 1987, Journal of surgical oncology.

[112]  A. Churg,et al.  Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma , 1984, The American journal of surgical pathology.

[113]  G. Pinkus,et al.  ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies. , 1990, The American journal of pathology.

[114]  H. Stein,et al.  Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. , 1990, Journal of clinical pathology.

[115]  D. Jones,et al.  Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium. , 1984, Journal of clinical pathology.

[116]  J. Oates,et al.  OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material. , 1995, Journal of clinical pathology.

[117]  Gregory B. Jobes,et al.  Differential expression of CD44S and hyaluronic acid in malignant mesotheliomas, adenocarcinomas, and reactive mesothelial hyperplasias , 1998 .